Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of zanidatamab plus chemotherapy with or without tislelizumab in first-line HER2-positive advanced gastroesophageal adenocarcinoma
CTR20212728Phase 3Active
- Sponsor
- 不适用/ 百济神州（北京）生物科技有限公司/ 百济神州（苏州）生物科技有限公司
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zanidatamab in gastroesophageal junction adenocarcinoma, sponsored by 不适用/ 百济神州（北京）生物科技有限公司/ 百济神州（苏州）生物科技有限公司. Started Jan 2022; status: active.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212728.